• CSL Behring, of King of Prussia, Pa., said European authorities approved an extended use of Berinert, a C1 esterase inhibitor concentrate, for pre-procedure prevention of acute episodes of hereditary angioedema in adult and pediatric patients undergoing medical, dental or surgical procedures.

• Eddingpharm, of Hong Kong, said it inked a joint venture (JV) agreement with Chiesi Farmaceutici SpA, of Parma, Italy, to establish Chiesi Edding Hong Kong Ltd. The JV is controlled 51 percent by Eddingpharm and 49 percent by Chiesi and will leverage Eddingpharm's marketing platform to facilitate wide and quick commercialization of key products of Chiesi in the respiratory therapeutic area in China.